Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.

Saved in:
Bibliographic Details
Title: Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.
Authors: Augustine M; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Division of Medicine, University College London, London, UK., Nene NR; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Department of Statistical Science, University College London, London, UK., Fu H; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK., Pinder CL; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Ligammari L; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Simpson AP; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK., Sanz-Fernández I; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK., Thakkar K; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Qian D; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Fitzsimons E; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Simpson BS; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Vendramin R; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Castro A; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Niederer H; Cancer Research Horizons, The Francis Crick Institute, London, UK., Turajlic S; Cancer Dynamics Laboratory, The Francis Crick Institute, London, UK.; Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.; Cancer Dynamics Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Quezada SA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.; Cancer Research UK City of London Centre, University College London, London, UK., McGranahan N; Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK., Watkins C; Department of Computer Science, Royal Holloway, University of London, London, UK., Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Department of Oncology, University College London Hospitals, London, UK., Litchfield K; Tumour Immunogenomics and Immunosurveillance (TIGI) Laboratory, University College London Cancer Institute, London, UK.; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Source: Nature machine intelligence [Nat Mach Intell] 2026; Vol. 8 (5), pp. 670-689. Date of Electronic Publication: 2026 May 18.
Publication Type: Journal Article
Journal Info: Publisher: Springer Nature Country of Publication: England NLM ID: 101740243 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2522-5839 (Electronic) Linking ISSN: 25225839 NLM ISO Abbreviation: Nat Mach Intell Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2522-5839
DOI:10.1038/s42256-026-01201-3